Robert F. Kennedy Jr., recently tapped for key health policy roles in Donald Trump’s campaign, is facing internal conflicts within his “Make America Healthy Again” initiative. Kennedy, a polarizing figure known for his controversial vaccine stance, is spearheading a reform movement aimed at reshaping public health and safety policies. However, divisions among his advisory team threaten to derail these efforts.
Long-term advisers focusing on vaccine safety are clashing with other team members advocating for broader public health reforms. Critics argue that Kennedy’s plans, such as altering the vaccine injury compensation program and opposing popular obesity drugs, could alienate key stakeholders, including healthcare professionals and pharmaceutical companies.

Despite successful appointments like Dr. Mehmet Oz and Dr. Marty Makary, these internal disagreements highlight the challenges of navigating a deeply divided healthcare landscape. The pharmaceutical industry, a powerful player, is expected to push back against Kennedy’s proposals, complicating their implementation.

For the general public, this adds to the uncertainty surrounding future healthcare reforms. While some hail Kennedy as a reformist who challenges the status quo, others worry that his controversial stances could do more harm than good. As the movement gains momentum, the question remains whether it can overcome internal and external hurdles to deliver meaningful change.

Read More News : Click Here